ALTIUM CAPITAL MANAGEMENT LP
Q2 2023 Form 13-F
NEW YORK, NEW YORK
CIK 0001746382
· Institutional investment manager
$132.1M Reported Value Total
Reported value
$132.1M
Quarter over quarter
+4.8%
Holdings
63
Top-10 concentration
58.7%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Mark Gottlieb
Chief Operating Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 14, 2023 |
| Form | 13F-HR |
| Reported value | $132.1M |
| Positions | 63 |
| Change in reported value | -26.7% |
| New positions | 16 |
| Exited positions | 41 |
| Position turnover | 54.8% |
| Top-10 concentration | 58.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 12, 2026
|
19 | $47.5M |
|
Q1 2026 13F
Filed May 1, 2026
|
19 | $42.0M |
|
Q4 2025 13F
Filed Feb 6, 2026
|
18 | $25.3M |
|
Q3 2025 13F
Filed Nov 4, 2025
|
1 | $628.3K |
|
Q2 2025 13F
Filed Aug 7, 2025
|
0 | $0 |
|
Q1 2025 13F
Filed May 9, 2025
|
22 | $41.5M |
|
Q4 2024 13F
Filed Feb 13, 2025
|
61 | $352.6M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
75 | $339.7M |
|
Q2 2024 13F
Filed Aug 15, 2024
|
64 | $245.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
67 | $252.7M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
62 | $147.3M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
65 | $191.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
63 | $132.1M |
|
Q1 2023 13F
Filed May 15, 2023
|
88 | $180.1M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
91 | $196.8M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
130 | $272.8M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
120 | $249.9M |
|
Q1 2022 13F
Filed May 16, 2022
|
117 | $298.8M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
131 | $362.7M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
121 | $381.3M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | KDNY CHINOOK THERAPEUTICS INC | $11.7M | 8.87% |
| 2 | ATXS ASTRIA THERAPEUTICS INC | $11.2M | 8.49% |
| 3 | IMGN IMMUNOGEN INC | $9.2M | 6.93% |
| 4 | ADMA ADMA BIOLOGICS INC | $8.8M | 6.65% |
| 5 | XENE XENON PHARMACEUTICALS INC | $8.8M | 6.64% |
| 6 | CBAY CYMABAY THERAPEUTICS INC | $7.3M | 5.54% |
| 7 | BONE XTANT MED HLDGS INC | $5.8M | 4.38% |
| 8 | HRMY HARMONY BIOSCIENCES HLDGS IN | $5.3M | 3.99% |
| 9 | GRI GRI BIO INC | $5.0M | 3.79% |
| 10 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $4.5M | 3.4% |
| 11 | RETA REATA PHARMACEUTICALS INC | $4.2M | 3.2% |
| 12 | AMLX AMYLYX PHARMACEUTICALS INC | $4.0M | 3.02% |
| 13 | JSPR JASPER THERAPEUTICS INC | $3.9M | 2.97% |
| 14 | ICPT INTERCEPT PHARMACEUTICALS IN | $3.6M | 2.7% |
| 15 | BBIO P BRIDGEBIO PHARMA INC | $3.4M | 2.6% |
| 16 | SRPT SAREPTA THERAPEUTICS INC | $3.2M | 2.43% |
| 17 | REPL REPLIMUNE GROUP INC | $3.0M | 2.28% |
| 18 | PHAT PHATHOM PHARMACEUTICALS INC | $3.0M | 2.25% |
| 19 | AXSM AXSOME THERAPEUTICS INC | $2.9M | 2.18% |
| 20 | OLMA OLEMA PHARMACEUTICALS INC | $2.8M | 2.12% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.